Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain

NCT00709202 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Schizophrenia
Schizoaffective Disorder
Schizophreniform Disorder
Bipolar I Disorder
Bipolar II
Bipolar NOS(Not Otherwise Specified)
Psychotic Disorder Not Otherwise Specified
Autism Spectrum Disorder

Interventions

DRUG: Betahistine
DRUG: Placebo Oral Tablet

Sponsor

Nathan Kline Institute for Psychiatric Research

Collaborators

[object Object]